Randomized placebo-controlled trial of emricasan for non-alcoholic steatohepatitis-related cirrhosis with severe portal hypertension

•Phase III trial comparing emricasan vs. placebo in patients with NASH-related cirrhosis and severe portal hypertension. •Despite evidence of target engagement, emricasan did not reduce portal hypertension in the overall study population. •The portal pressure-reducing effect may be more evident in latter stages of portal hypertension. •Treatment-emergent adverse events were similar between emricasan and placebo. Background & Aims Emricasan, an...